Professor of Medicine
Director, GI Physiology Laboratory
Co-Director, Michigan Bowel Control Program
H. Marvin Pollard Institute Scholar
Division of Gastroenterology
University of Michigan Health System
Ann Arbor, Michigan

BIOGRAPHY
Dr Chey received his BA degree from the University of Pennsylvania and medical degree & training in internal medicine at the Emory University School of Medicine. He went on to complete a fellowship in gastroenterology at the University of Michigan in Ann Arbor. Since completing this fellowship, Dr Chey has remained at the University of Michigan, where he is currently a Professor of Medicine in the Division of Gastroenterology, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program. In 2011, Dr. Chey was named as the inaugural H. Marvin Pollard Institute Scholar at the University of Michigan Health System.

His research interests focus on the diagnosis and treatment of the functional bowel disorders, acid-related disorders, and Helicobacter pylori (H. pylori) infection. Dr Chey has received funding for his research from federal and private sources.

Dr Chey has authored more than 250 manuscripts, reviews and book chapters. He is Co-editor-in-Chief of the American Journal of Gastroenterology (2010-2013), Clinical & Translational Gastroenterology (2011-2013) and serves on the editorial boards of several other medical journals.

He serves as a member of the Board of Trustees, Practice Parameters Committee and Publications Committee of the American College of Gastroenterology. He plays an active role in the Rome Foundation and recently joined the Board of Directors in 2010. Dr. Chey is a member of the planning committee for the development of the Rome IV criteria and is Co-chair of the Rome Foundation Working Group addressing the role of food in the pathogenesis and treatment of functional GI disorders. He is a member of the Advisory Board of the International Foundation of Functional GI Disorders. He is past Chair of the Clinical Practice Section (2006-2008) of the American Gastroenterological Association.

He has participated in and directed numerous national and international continuing medical education programs in gastroenterology, and has been elected to the roster of “Best Doctors” since 2001 and “America’s Top Doctors” since 2009. Dr. Chey was named as one of the “125 Best Gastroenterologists in America” by Becker’s ASC in 2012.

ADDITIONAL INFORMATION
Best Doctors in America 2001 to present
America’s Top Doctors – Castle Connolly 2010 to present
Top 1% of US Gastroenterologists – US News and World Report – 2012
75 Best Gastroenterologists in America – Beckers ASC Review 2010
125 Best Gastroenterologists in America – Beckers ASC Review - 2012

With Dr. Dee Fenner, Dr. Chey serves as co-director of the Michigan Bowel Control Program (MBCP). The MBCP is a unique multispecialty program which provides care to patients with complicated disorders of defecation including chronic constipation and fecal incontinence. Depending upon their individual needs, patients may be seen by physicians from gastroenterology, urogynecology, colorectal surgery, and physical medicine. A tremendous benefit to patients cared for by the MBCP is the expert support provided by the program’s dedicated nurse concierges. The MBCP program is supported by a number of outstanding ancillary services including physical therapy, nutrition, and psychology. The multidisciplinary team approach provides streamlined, comprehensive care for patients who have typically been seen by multiple physicians at wide range of local and national medical centers. In the past several years, the MBCP has seen a growing number of patients who travel long distances for the program’s expertise. This reflects the fact that the MBCP is one of only a handful of such truly multidisciplinary programs nationally. Founded in 2004, the MBCP has enjoyed steady growth on a variety of fronts. The number of physician providers has grown from 3 (Chey, Fenner, Huang) in 2004 to 7 representing 4 specialties (GI, Urogynecology, Colorectal Surgery, Physical Medicine) in 2012. New patient visits has grown from 110 in 2004 to over 400 in the academic year 2011-12.

Dr. Chey also serves as director of the Gastrointestinal (GI) Physiology Laboratory. This state of the art lab serves as a unique resource for University Health System and community providers by performing a wide range of services including esophageal, antroduodenal, and anorectal manometry, breath testing for small intestinal bacterial overgrowth, carbohydrate malabsorption, and H. pylori infection, ambulatory esophageal and gastric pH/impedance monitoring, gastric acid analysis, whole gut and colonic transit testing, pudendal nerve latency testing and capsule endoscopy. Recent additions by the lab have included ambulatory esophageal impedence/pH testing, high resolution esophageal manometry, and wireless motility/pH capsule testing. The laboratory has enjoyed impressive growth over the past 10 years. In 2003, 997 procedures were performed by the laboratory. In 2011, more than 3000 procedures were performed by laboratory. The laboratory is one of only 2 such comprehensive GI physiology laboratories in the Midwest. The American Neurogastroenterology and Motility Society has designated the GI Physiology Lab of the University of Michigan as a center of excellence. The laboratory recently underwent a comprehensive renovation and as part of that process won an award from the University for design of an ergonomically sensitive workplace.

Dr. Chey has also played an important role in development of the Division of Gastroenterology’s nutrition services. With the assistance of Christine Dubois, a RD at UM, Dr. Chey helped to develop and introduce the low fodmap approach to the Division of Gastroenterology in 2008. Over the last 4 years, this dietary intervention has gained popularity amongst the faculty of the Division of Gastroenterology and is now considered a first line strategy for IBS patients with food related symptoms. He played a key role in the recent hiring of a dedicated registered dietician for the Division of Gastroenterology. With the assistance of Dr. Shanti Eswaran, he is initiating the first large, methodologically rigorous, randomized, controlled US trials evaluating the low fodmap diet in patients with IBS. His expertise in this topic has been acknowledged by invitations to speak about the science behind and UM experience with dietary interventions for IBS at Digestive Diseases Week 2012 and a growing number of academic institutions including Northwestern University, the Mayo Clinic Rochester (Hugh Butt Visiting Professorship), University of Iowa (H. Joyce Miller Visiting Professorship), University of Washington, and Indiana University.

University of Michigan

The Division of Gastroenterology is one of the largest gastroenterology practices in the country and is a leader in the prevention, diagnosis, and treatment of diseases of the gastrointestinal tract and liver. 40-plus physicians are experts in the diagnosis and treatment of all diseases of the gastrointestinal system, from simple to complex, including those of the esophagus, stomach, small intestine, colon, rectum, liver, gallbladder, pancreas, and biliary tract.

In addition to being leaders in the clinic, the faculty are also leaders in their respective areas of research, which span such varied interests as the role of peptides in the brain-gut interactions in functional bowel diseases to innovative treatments of viral hepatitis and liver cancer.

 The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.

 Food: the forgotten factor in the irritable bowel syndrome

 A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation.

 Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

 Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders.

 Factors associated with quality of life among women with fecal incontinence.

 Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.

 Abnormal immune regulation and low-grade inflammation in IBS: does one size fit all?